MAPT and Alzheimer disease: For instance, glutamine levels are lower in the brains of Alzheimer’s disease (AD) patients, and glutamine supplementation (GS) can reduce inflammation-induced neuronal cell cycle activation, tau phosphorylation, and ATM (ataxia telangiectasia mutation)activation in an AD mouse model (Chen et al., 2012).